Founded with the goal of revolutionizing precision medicine, Surge is an innovative company specializing in in-depth understanding of the immune system using AI. Thanks to significant technological advancements and a team of top-notch researchers coming from the US and from France, Surge is committed to creating innovative solutions to pave the way for personalized medicine of tomorrow. With the launch of its first product, PreCyte®, for predicting the risk of postoperative complications, and its premier laboratory, SurgeLab™, for acquiring individualized immune signatures, the company aims to become a leader in precision immune analysis.

SurgeCare develops two main products :
– SurgeLab™, a lab platform focused on acquiring immune signatures, and
– PreCyte®, a range of medical devices for precision medicine.

Founded in 2021 with innovative technology for identifying predictive immune biomarkers, Surge, from 2021 to 2023, developed a first prototype to anticipate the risk of post-operative infections in patients undergoing major digestive surgery. A clinical study conducted from 2022 to 2023 revealed that their prototype outperforms existing methods by more than three times in terms of predictive capability. In 2024, this prototype enters its final phase of industrialization, with deployment planned as a pilot in the fourth quarter of 2024.

Meanwhile, in response to the growing interest of their partners, they have initiated the opening of their SurgeLab platform, which offers comprehensive immune screening, including ex-vivo blood stimulation, collection of biological parameters via a specialized panel, and data analysis through machine learning, reinforcing their commitment to innovation in precision medicine.

–  Therapeutic areas: Surgery, Immunology, Precision Medicine

–  Based in: Strasbourg (FRANCE) & Stanford University (StartX) (USA)

–  Employees: 11 – 50

–  Created in: 2021